1 Fifty per cent of first-degree relatives of index cases with familial 2 hypercholesterolemia (FH) inherit the disorder. Despite cascade screening being the 3 most cost-effective method for detecting new cases, only a minority of individuals 4 with FH are currently identified. Primary care is a key target area to increase 5 identification of new index cases and initiate cascade screening, thereby finding 6 close relatives of all probands. Increasing public and health professional awareness 7 about FH is essential. 8 In the United Kingdom and in Australia, most of the population are reviewed by a 9 General Practitioner (GP) at least once over a three-year period, offering 10 opportunities to check for FH as part of routine clinical consultations. Such 11 opportunistic approaches can be supplemented by systematically searching 12 electronic health records with information technology tools that identify high risk 13 patients. GPs can help investigate and implement results of this data retrieval. 14 Current evidence suggests that early detection of FH and cascade testing meet most 15 of the criteria for a worthwhile screening program. Among heterozygous patients the 16 long latent period before the expected onset of coronary artery disease provides an 17 opportunity for initiating effective drug and lifestyle changes. The greatest challenge 18 for primary care is to implement an efficacious model of care that incorporates 19 sustainable identification and management pathways.
Introduction
including busy clinical settings at tertiary and primary care level, pressure on bed lifelong treatment and management strategies 3, 9, 12 . To achieve such radical care In Slovenia, the use of universal screening for children aged over 5 years has been attendances by children aged 1 -2 years at 92 general medical practices in the levels in high risk patients, a family or personal history of premature CAD or death 23 plus recognition of other tell-tale stigmata of FH, will be necessary 1, 3 . 1 Opportunities to increase detection of FH in general practice are becoming more 2 sophisticated. New data extraction tools employing algorithms of the phenotypic 3 features of FH (Dutch Lipid Clinic Network (DLCN) 42 , Make Early Diagnosis to 4 Prevent Early Deaths (MEDPED) 43 and Simon-Broome (S-B) criteria 44 ) can minimise 5 practice workloads while still focussing attention on detecting high risk patients. 6 In Australia, there have been attempts at improving detection and management of 7 FH in the primary care sector 33, 45-47 . Models of care, which in the past have focussed 8 on tertiary level hospital lipid clinics 3 , are now looking at a greater involvement from 9 primary care especially for patients without additional risk factors 22, 41 .
Extra workloads

10
Phenotypic v genetic testing 11 The DLCN criteria (DLCNC) score 42 is the preferred tool in Australia to help with 12 phenotypic diagnosis of FH 26 . Cost, geographic and migration factors, plus lack of 13 population density across most of the continent, are major handicaps towards use of 14 genetic testing for all suspected FH patients 22 . The same barriers also preclude the 15 widespread use of dedicated field workers 27 to undertake systematic contact tracing 16 of close relatives. A more pragmatic approach involving use of the DLCNC score in 17 the primary care setting is currently being trialled in Australia 47 . 18 The use of genetic testing in the UK compared with the phenotypic approach 19 advocated in Australia and in the United States offers an interesting comparison 34 . 
17
The absence of suitable infrastructure in primary care to assist with cascade testing 18 of relatives is a major handicap 2 . Serious deficiencies have been found in patient 19 knowledge about FH, their risk of a major cardiac event and the mode of inheritance 20 across generations 50 .
21
General practice search strategies 22
Gray et al. 35 undertook computer-based searches to look for likely FH patients at a 23 primary care centre of 12,000 patients in South London. A total of 402 individual patients were identified for review. After record review and using the DLCNC 1 score 42 , they identified 12 patients who scored 8 and above ('definite' FH); eight who 2 score between 6 and 8 ('probable' FH) and a further 47 patients who scored between 3 3 and 5 ('possible' FH). Thus, a total of 20 patients met the criteria for 'definite' or 4 'probable' FH in the study. No cases with tendon xanthomata were found.
5
All patients with FH were noted to have early CAD and the authors concluded this 6 finding as the key to reaching a diagnosis of FH. Commencement of treatment for 7 elevated lipids with statins was noted to occur without the potential for FH being the 8 key diagnosis being considered. This lost opportunity to screen close family 9 members for the condition could have contributed to avoidable mortality in the approach to be seen early if they change their mind re future treatments. 10 6. Improve health professional awareness of FH 11 Despite increasing knowledge about the prevalence and risks of FH, many health 12 professionals do not make a connection between FH and the patient's presenting 13 condition 3, 6, 50 . A better appreciation of the underlying genetic nature of the 14 disease 10, 13, 61 and the fact that it will not be solely responsive to dietary and lifestyle 15 intervention is needed. 16 The current best management approach is through use of high intensity statins from 17 a young age 1, 9, 11, 12, 14, 26, 62 . The lifetime increased accumulation of LDL-c means 18 that the relative risk from FH makes the use of absolute CVD risk calculators 63 19 inappropriate in patients with FH and they should not be used 1, 9, 11, 14, 26 . Compliance The traditional model of care for FH is based on the chronic care model 3, 32 and aims 6 to deliver the right treatment, for the right patient, at the right time, by the right team 7 across the continuum of care. Of necessity, this will involve a major contribution from 8 primary care but patients with the condition are not being recognised during routine 9 clinical encounters 1, 9, 14 . The current infrastructure in primary care makes cascade 1, 3, 9 . (2) The objective of screening should be defined at the outset.
• Identification of patients at very high risk of premature CHD 1, 3, 9 . • High intensity lipid lowering treatment can lead to 48% reduction in CHD mortality 1, 3, 9 . (3) There should be a defined target population.
Less consensus, but is based on an interplay of an individual's cholesterol levels and family history of premature coronary heart disease, familial hypercholesterolemia and/or raised cholesterol eg:
• Cholesterol levels > 9.3 mmol/l indicated FH in 28% of patients 60 • Cholesterol levels > 7.5mmol/l should trigger further assessment of FH 2, 35 • Personal or family history of premature CHD 17 • Diagnostic criteria such as the DLCN 42 , MEDPED 43 and S-B criteria 44
(4) There should be scientific evidence of screening programme effectiveness.
Case series and interventional studies 49 show improvement in the number of new cases identified with possible or definite FH.
(5) The programme should integrate education, testing, clinical services and programme management.
Several countries integrate preventative programmes and care pathways from primary to specialist care 1, 3, 9 (see section "Potential approaches to screening in primary care").
(6) There should be quality assurance, with mechanisms to minimise potential risks of screening.
• Lipid tests are available to internationally recognised standard (currently ISO 17043 in UK and NPAAC 83 in Australia) • Family history recording of a three generation pedigree is standard in specialist care but the requirement for primary care is unclear. This could be a detailed family history collection or a less sensitive method of a few direct questions 84 • Genetic testing will require agreed standard of testing and interpretation prior to adoption. Currently the gold standard is NGS 69, 85, 86 as a cost saving method 87,88 but risks missing phenotypic FH 3 . • Reducing premature CHD is the prime target of FH screening 1, 3, 9 . • The false positive diagnostic rate 44 is a potential harm but better use of algorithms (FAMCAT 36 and TARB-Ex 33 ) may increase specificity • The psychological impact of a diagnosis is considered minimal but evidence for short-term increase in anxiety is recognised 56, 57 
